HLT — Hilton Worldwide Holdings Inc.

Sell-side and tape disagree sharply as of 2026-09-13. Analyst consensus is Buy (28 buys, 21 holds, 0 sells) with a $348.11 consensus target and a $359.67 recent-average target, implying ~14-17% upside from the $306.19 price; management also raised FY2026 guidance on the 2026-07-28 print (RevPAR +3.0-3.5%, adj. EBITDA $4.04-4.08B). The market, however, has been selling: -1.6% on the week, -5.07% on the month, -11.49% over three months, RSI(14) at 36.85, and price below all three key SMAs. The de-rating looks driven by multiple fatigue (44.5x trailing P/E, 26.9x trailing EV/EBITDA), soft Q2 international performance (Middle East RevPAR roughly -30%) and Q2 operating cash flow falling to $472M from $658M a year earlier, rather than by any break in the fee-growth story.

Revenue growth is real but decelerating: Q2 2026 revenue $3.341B (+6.5% YoY vs $3.137B), Q1 2026 $2.937B (+9.0% vs $2.695B), Q4 2025 $3.087B (+10.9% vs $2.783B), Q3 2025 $3.120B (+8.8% vs $2.867B) - a glide from ~11% to ~6.5%, which is normalization rather than deterioration. Margins are clearly expanding: operating margin of 25.7% in Q2 2026 vs 24.8% a year earlier, 23.1% in Q1 2026 vs 19.9%, 19.5% in Q4 2025 vs 17.6%, and 24.9% in Q3 2025 vs 21.7% - four consecutive quarters of YoY margin expansion. EPS is compounding: $2.10 in Q2 2026 vs $1.84, $1.66 in Q1 2026 vs $1.23, $1.77 in Q3 2025 vs $1.38; the only optical dip is Q4 2025's $1.28 vs $2.05, and that comparison is polluted because Q4 2024 net income ($505M) exceeded operating income ($489M), i.e. a non-operating gain. The genuine soft spot is cash: Q2 2026 operating cash flow of $472M was 28% below Q2 2025's $658M, and TTM free cash flow of ~$1.989B (Q3'25-Q2'26: $766M + $151M + $609M + $463M) is down from ~$2.198B a year earlier - though Q1 2026 OCF was up 37% YoY, so the weakness is timing-lumpy, not a clean downtrend. Net: this is a stable-to-slightly-decelerating top line with expanding margins and noisy cash conversion, not a cyclical trough and not a structural break.

Expensive in absolute terms, roughly neutral versus its own history. At $306.19 on 2026-09-13, HLT carried a 44.5x trailing P/E on $6.978 TTM EPS, a 9.76 PEG, 5.52x sales (vs. a 5.45x 5-year average) and 0.23x the S&P 500's dividend yield (0.184%). Against the next-FY EPS estimate of $9.04, the forward P/E is ~33.9x - a large premium to the broad market for a business compounding EPS at roughly 9% off that base. The trailing multiple is below the 5-year average P/E of 52.41, which is why the valuation context reads 'Neutral vs. its own history' (58.6/100), but that historical average is inflated by the 2023 earnings trough. On EV/adjusted EBITDA the picture is more defensible: EV of ~$80.6B (market cap $68.9B + $12.719B long-term debt - $1.009B cash) against FY2026 guided adjusted EBITDA of $4.04-4.08B is ~19.8x, a premium to Marriott-type peers but not absurd for 6.1% net unit growth. Price-to-book (-11.03x) and ROE (-0.27) are meaningless here given $-6.303B of stockholders' equity, and debt-to-equity is distorted for the same reason. Verdict: fully valued, not cheap; the multiple leaves no room for a RevPAR miss.

This is a textbook estimate-up / price-down divergence. Hilton beat Q2 2026 (adjusted EPS $2.29 vs $2.25-2.26 consensus) and raised FY2026 guidance, yet the shares fell ~2.5-3.4% on the print and are down 11.49% over three months. That means the market is compressing the multiple, not marking down the earnings - the 'E' is fine, the 'P/E' is the problem. Practically: if HLT delivers the $9.04 next-FY EPS estimate, an investor buying at $306.19 is paying ~34x; upside from here requires either multiple re-expansion (lower rates, re-accelerating RevPAR) or faster-than-expected per-share compounding from the ~$3.5B capital-return program on top of 6% net unit growth. Conversely, if system-wide RevPAR growth slips below the guided 3.0-3.5%, there is no cheap multiple to cushion the fall - a 30x forward multiple on $9.04 is $271, about 11% below the 2026-09-13 price.

Bearish-to-neutral tape as of 2026-09-13. RSI(14) was 36.85 - weak momentum but not oversold, so no mean-reversion signal yet. Price was below the 20-day (-4.33%), 50-day (-5.15%) and 200-day (-2.36%) SMAs, with returns of -1.6% (1 week), -5.07% (1 month), -11.49% (3 months) against +5.02% (6 months) - a downtrend inside a wider range (52-week range $253.54-$358.00). Entry-timing implication: there is no technical reason to chase here. The constructive setup would be an RSI push below 30 with a reclaim of the 200-day SMA; the level to watch if the downtrend extends is the $253.54 52-week low, roughly 17% below the 2026-09-13 price.

• Interest rates: elevated financing costs are suppressing new-build hotel construction for independent developers, which slows industry supply growth - a medium-term tailwind for incumbents' RevPAR - while simultaneously raising Hilton's own cost of the ~$12.7B of long-term debt on the balance sheet.
• Travel demand bifurcation: high-end, group and corporate travel remain resilient (US RevPAR +5.4% in Q2 2026, system-wide +3.9% currency-neutral), while low-to-middle-income leisure shows fatigue - a mix risk that disproportionately matters if the consumer weakens further.
• Geopolitical shocks: Middle East RevPAR fell roughly 30% in Q2 2026, a concrete, localized drag on international segment margins that is outside management's control.
• Consumer discretionary cyclicality: fee income is high-margin and high-operating-leverage, so a broad RevPAR downturn would hit EBITDA and EPS faster than it hits revenue - the main macro downside lever in a recession.
• Capital-markets conditions for the capital-return story: the $3.5B 2026 shareholder return target and the May 2026 $1.0B 5.500% senior notes due 2031 both depend on continued access to reasonably priced debt.

• Q3 2026 earnings, expected late October 2026: management guided Q3 adjusted EBITDA of $1.035-1.055B and EPS of $2.28-2.34, citing calendar shifts and major global events including the World Cup - a clean read on whether RevPAR momentum is holding.
• Execution on the record 541,300-room pipeline (5,400+ properties, +6% YoY) and delivery of the 6%+ net unit growth target, which is the engine behind fee-revenue compounding independent of RevPAR.
• Pacing of the ~$3.5B 2026 capital return (buybacks plus the token 0.184% dividend) - each $3.5B retired at this market cap is roughly 5% of shares outstanding, a direct EPS tailwind.
• New-brand contributions, including Undergraduate by Hilton launched June 2026 targeting college/university markets - immaterial now, but a signal on the long-run unit-growth runway.
• Any resolution or de-escalation of Middle East conflict, which would reverse the ~30% RevPAR decline in that region and lift international segment margins.

• Valuation risk is the dominant one: ~33.9x forward EPS (~19.8x FY2026E adjusted EBITDA) on a business compounding EPS at roughly 9% off the forward base means a RevPAR or unit-growth miss gets punished by multiple compression, not just estimate cuts.
• Cash-flow quality: Q2 2026 operating cash flow dropped 28% YoY to $472M and TTM free cash flow of ~$1.989B is below the prior-year ~$2.198B - if this is not just timing, the buyback-funded EPS growth story weakens.
• Balance-sheet structure: $-6.303B stockholders' equity, 0.649 current ratio and $12.719B of long-term debt leave little cushion, and they make standard solvency ratios (debt/equity, P/B, ROE) uninterpretable - the company's flexibility depends on continued free cash flow and refinancing access.
• Revenue growth deceleration from ~10.9% YoY in Q4 2025 to 6.5% in Q2 2026 - if unit growth or RevPAR slows further, the premium multiple has nothing to lean on.
• Geopolitical/regional concentration of the downside: the Middle East drag (-30% RevPAR) hit a segment that is a meaningful part of the international fee-growth story, and the next shock may not be as contained.
• Consumer cyclicality: low-to-mid-income leisure travel fatigue could broaden into a broader RevPAR slowdown, and fee-based revenue has high operating leverage to occupancy.

Hilton is a genuinely high-quality, capital-light fee machine - record 541,300-room pipeline, 6.1% net unit growth, four straight quarters of YoY operating-margin expansion, 23.3% TTM operating margin, 15.4% ROIC, an $8.30ish FY2026 EPS guide versus $6.978 TTM, and a $3.5B buyback - but at $306.19 on 2026-09-13 the shares already pay for that quality at ~34x forward earnings and ~20x forward adjusted EBITDA against a 2.9% free-cash-flow yield and a 0.184% dividend. My fair value of $312 implies about 2% upside, and the tape is in a downtrend below all key moving averages. This is a great business at a full price - I would not be a buyer here, and would rather wait for the low-to-mid $270s (~30x forward) or for evidence that RevPAR growth is re-accelerating above the guided 3.0-3.5%.

Blended two forward-looking methods as of 2026-09-13: (1) a justified forward P/E of 35x on the next-FY EPS estimate of $9.04 = $316.40, set within HLT's historical forward range and reflecting ~9-11% EPS compounding from 6% net unit growth, ~3% RevPAR, and ~5%/yr share shrinkage from the $3.5B capital return; and (2) 20x FY2026 guided adjusted EBITDA of $4.06B (midpoint of $4.04-4.08B) = $81.2B EV, less net debt of ~$11.71B ($12.719B long-term debt minus $1.009B cash) = $69.5B equity, divided by ~225.1M shares (from the $68.9126B market cap at $306.19) = $308.80. Averaging the two gives $312.59, rounded to $312 - roughly 2% above the $306.19 price and below the $316 low end of the published analyst target range, because I do not think a ~34x forward multiple is justified for a business whose revenue growth has decelerated to 6.5% YoY.